Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atenolol Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

NCT04755764
View directory record Official record
Conditions
Systolic Hypertension, Pregnancy Related, Diastolic Hypertension, Cardiac Output, Low, Cardiac Output, High
Interventions
Labetalol, Atenolol, Nifedipine
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 25, 2026, 6:27 AM EDT
Terminated Not applicable Interventional Results available

Multimodal Treatment Strategy for Cancer Cachexia

NCT00625742
View directory record Official record
Conditions
Advanced Cancer, Cachexia
Interventions
Graded Resistance Training, Aerobic Exercise, Melatonin, Juven, Atenolol, Ibuprofen
Behavioral · Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2005 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism

NCT02467400
View directory record Official record
Conditions
Osteoporosis, Age-Related
Interventions
Atenolol, Nebivolol, Propranolol, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Determinants of Response to Beta Blockade

NCT00837902
View directory record Official record
Conditions
Healthy
Interventions
Atenolol (β-blocker)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277
View directory record Official record
Conditions
Healthy
Interventions
Atenolol 50 MG, Placebo
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scarborough, Maine • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects

NCT02262533
View directory record Official record
Conditions
N/A - Healthy Subjects
Interventions
Apixaban, Atenolol
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 25, 2026, 6:27 AM EDT
Withdrawn Early Phase 1 Interventional

Impedance Cardiography to Decrease the Risk of Preeclampsia

NCT03245970
View directory record Official record
Conditions
Chronic Hypertension Complicating Pregnancy (Diagnosis), Preeclampsia
Interventions
Labetalol Hydrocholoride 200 mg orally every 12 hours, Nifedipine 60 mg orally daily, Atenolol 25 mg daily
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
18 Years to 51 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 4 Interventional

Elder Surgery - Functional Recovery Following Beta Blockade

NCT00507663
View directory record Official record
Conditions
Post Operative Cognitive Dysfunction
Interventions
Atenolol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 25, 2026, 6:27 AM EDT
Terminated Phase 3 Interventional Results available

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

NCT00589303
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Not applicable Interventional Results available

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

NCT00911508
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Left atrial ablation, Rate or Rhythm Control Therapy
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
76
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

NCT01522950
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, atenolol, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 25, 2026, 6:27 AM EDT
Withdrawn Phase 4 Interventional

EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network

NCT01748123
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone, Hydrochlorothiazide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 4 Interventional

Vascular Improvement With Olmesartan Medoxomil Study

NCT00772499
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2008 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques

NCT01230892
View directory record Official record
Conditions
Atherosclerosis, Endothelial Function
Interventions
Nebivolol, Atenolol
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 79 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

NCT00723801
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Atenolol, Losartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 25, 2026, 6:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

NCT03070730
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Droxidopa, Atenolol, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

NCT00158093
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Atenolol, Moxifloxacin
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2005 · Synced Sep 25, 2026, 6:27 AM EDT
Enrolling by invitation Phase 4 Interventional

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07298993
View directory record Official record
Conditions
Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Placebo (matching), Beta-blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Nebivolol in the Treatment of Hypertension in African Americans

NCT00145210
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Sep 25, 2026, 6:27 AM EDT
Withdrawn Phase 2 Interventional

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354
View directory record Official record
Conditions
Vestibular Migraine, Migraine Disorders, Vestibular Diseases
Interventions
4-aminopyridine, Atenolol, Placebo
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 25, 2026, 6:27 AM EDT
Not listed Early Phase 1 Interventional

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

NCT03105661
View directory record Official record
Conditions
Obesity, Morbid, Preeclampsia
Interventions
Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Results available

Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure

NCT00669279
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 25, 2026, 6:27 AM EDT
Completed Not applicable Interventional

Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

NCT00607347
View directory record Official record
Conditions
Hypertension
Interventions
Glucose
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 25, 2026, 6:27 AM EDT